Roflumilast for oral ulcers in Behçet’s disease and recurrent aphthous stomatitis

Single-center, single-arm, retrospective, observational investigation of low-dose roflumilast for refractory OUs in BD and RAS with 46 subjects, screened from outpatient department from May 2023 to Dec 2023. Objective clinical response is assessed by the treating dermatologist regarding to Investigator’s global assessment, subjective responses as assessed by a patient-reported questionnaire, and adverse events monitored through the study protocol